Preclinical characterization of AZD1163, a first-in-class anti-PAD2/4 bispecific antibody for the treatment of rheumatoid arthritis.
Saved in:
| Title: | Preclinical characterization of AZD1163, a first-in-class anti-PAD2/4 bispecific antibody for the treatment of rheumatoid arthritis. |
|---|---|
| Authors: | Sims GP; Immunology Biosciences, Respiratory and Immunology, BioPharmaceuticals R&D, AstraZeneca, Gaithersburg, USA., Scaletta L; Immunology Biosciences, Respiratory and Immunology, BioPharmaceuticals R&D, AstraZeneca, Gaithersburg, USA., Andrews J; R&D, Biologics Engineering, AstraZeneca, Cambridge, UK., Sims DA; Immunology Biosciences, Respiratory and Immunology, BioPharmaceuticals R&D, AstraZeneca, Gaithersburg, USA., Strain M; R&D, Biologics Engineering, AstraZeneca, Cambridge, UK., Sigurdardottir A; R&D, Biologics Engineering, AstraZeneca, Cambridge, UK., Kuriakose T; Immunology Biosciences, Respiratory and Immunology, BioPharmaceuticals R&D, AstraZeneca, Gaithersburg, USA., England E; R&D, Biologics Engineering, AstraZeneca, Cambridge, UK., Rajasinghe L; Immunology Biosciences, Respiratory and Immunology, BioPharmaceuticals R&D, AstraZeneca, Gaithersburg, USA., Jiang F; Translational Science and Experimental Medicine, Respiratory and Immunology, BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden., Xiong X; Immunology Biosciences, Respiratory and Immunology, BioPharmaceuticals R&D, AstraZeneca, Gaithersburg, USA., Neal F; R&D, Biologics Engineering, AstraZeneca, Cambridge, UK., Vinall L; R&D, Biologics Engineering, AstraZeneca, Cambridge, UK., Newton P; R&D, Biologics Engineering, AstraZeneca, Cambridge, UK., Boger E; DMPK, Respiratory and Immunology, BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden., Kim C; Integrated Bioanalysis, Biopharmaceuticals R&D, AstraZeneca, Gaithersburg, United Sates of America., Dahlbäck H; DMPK, Respiratory and Immunology, BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden., Prothon S; Clinical Pharmacology and Quantitative Pharmacology, Clinical Pharmacology and Safety Sciences, BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden., Leander J; Clinical Pharmacology and Quantitative Pharmacology, Clinical Pharmacology and Safety Sciences, BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden., Darrah E; Translational Science and Experimental Medicine, Respiratory and Immunology, BioPharmaceuticals R&D, AstraZeneca, Gaithersburg, USA., Collins M; Translational Science and Experimental Medicine, Respiratory and Immunology, BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden., Douglas G; Clinical Pharmacology and Safety Sciences, BioPharmaceuticals R&D, AstraZeneca, Cambridge, UK., White N; Integrated Bioanalysis, BioPharmaceuticals R&D, AstraZeneca, Cambridge, UK., Day K; Biopharmaceutical Development, BioPharmaceuticals R&D, AstraZeneca, Cambridge, UK., Vousden KA; R&D, Biologics Engineering, AstraZeneca, Cambridge, UK., Huntington CE; R&D, Biologics Engineering, AstraZeneca, Cambridge, UK., Close D; Clinical Development, Respiratory and Immunology, BioPharmaceuticals R&D, AstraZeneca, Cambridge, UK. |
| Source: | MAbs [MAbs] 2026 Dec; Vol. 18 (1), pp. 2657629. Date of Electronic Publication: 2026 Apr 15. |
| Publication Type: | Journal Article |
| Journal Info: | Publisher: Taylor & Francis Country of Publication: United States NLM ID: 101479829 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1942-0870 (Electronic) Linking ISSN: 19420862 NLM ISO Abbreviation: MAbs Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
Be the first to leave a comment!
